Published in Bioorg Med Chem Lett on September 19, 2010
Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators. Pharmacol Ther (2014) 0.76
A High Throughput Assay for Discovery of Small Molecules that Bind AMP-activated Protein Kinase (AMPK). Curr Chem Genom Transl Med (2013) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol (2006) 4.28
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett (2008) 2.51
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans (2002) 2.47
Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ (2008) 2.45
AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol (2010) 1.93
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther (2010) 1.49
Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem (2008) 1.41
Grand canonical Monte Carlo simulation of ligand-protein binding. J Chem Inf Model (2006) 1.11
AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem (2008) 1.08
A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulation. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.05
Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2. J Biol Chem (2006) 1.00
Improved naïve Bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J Chem Inf Model (2006) 0.99
Fast protein structure prediction using Monte Carlo simulations with modal moves. J Am Chem Soc (2003) 0.95
Fragment-based computation of binding free energies by systematic sampling. J Chem Inf Model (2009) 0.94
Grand canonical free-energy calculations of protein-ligand binding. J Chem Inf Model (2009) 0.85
NMR-guided fragment-based approach for the design of tRNA(Lys3) ligands. Angew Chem Int Ed Engl (2007) 0.85
Maximizing discovery efficiency with a computationally driven fragment approach. Curr Opin Drug Discov Devel (2005) 0.82
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther (2010) 1.49
A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol Ther (2009) 1.47
Double belt structure of discoidal high density lipoproteins: molecular basis for size heterogeneity. J Mol Biol (2004) 1.36
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry (2010) 1.00
Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br J Pharmacol (2012) 0.99
Enrichment of extremely noisy high-throughput screening data using a naïve Bayes classifier. J Biomol Screen (2004) 0.94
A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogen-activated protein kinase. Anal Biochem (2004) 0.93
Pathway logic: symbolic analysis of biological signaling. Pac Symp Biocomput (2002) 0.88
Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1. Bioorg Med Chem Lett (2010) 0.81
Technique for generating three-dimensional alignments of multiple ligands from one-dimensional alignments. J Chem Inf Model (2008) 0.81
How can we improve antibody-based cancer therapy? MAbs (2010) 0.80
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent. J Med Chem (2010) 0.79
Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation. Bioorg Med Chem Lett (2009) 0.79
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Bioorg Med Chem Lett (2011) 0.78
SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis (2010) 0.78
The metal-responsive transcription factor-1 protein is elevated in human tumors. Cancer Biol Ther (2010) 0.77
Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett (2005) 0.77
Changes to NIH grant system may backfire. Science (2008) 0.75
Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases. J Chem Inf Model (2010) 0.75
Freely available software programs for drug discovery. Curr Top Med Chem (2012) 0.75
Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR. Chem Biol (2002) 0.75
Computational approach to de novo discovery of fragment binding for novel protein states. Methods Enzymol (2011) 0.75